



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

GLX351322

Cat. No.:	HY-100111
CAS No.:	835598-94-2
Molecular Formula:	C ₂₁ H ₂₅ N ₃ O ₅ S
Molecular Weight:	431.51
Target:	NADPH Oxidase
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 20 mg/mL (46.35 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.3174 mL	11.5872 mL	23.1744 mL
		5 mM		0.4635 mL	2.3174 mL	4.6349 mL
		10 mM		0.2317 mL	1.1587 mL	2.3174 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 50% PEG300 >> 50% saline Solubility: 25 mg/mL (57.94 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (4.82 mM); Suspended solution; Need ultrasonic					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC ₅₀ of 5 μM.
IC ₅₀ & Target	NOX4
In Vitro	GLX351322 is an inhibitor of NADPH oxidase 4, and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC ₅₀ of 5 μM. GLX351322 shows weak activity against NOX2 in hPBMC cells (IC ₅₀ , 40 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GLX351322 (3.8 mg/kg/day, p.o.) ameliorates HFD-induced hyperglycemia in mice^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Alzheimers Dement. 2020;16(Suppl. 3):e038198.
- Cell Mol Biol Lett. 2023 Mar 23;28(1):24.
- Int J Biol Macromol. 2021 Jul 23;S0141-8130(21)01587-7.
- Free Radic Biol Med. 2023 Jul 27;S0891-5849(23)00548-8.
- Free Radic Biol Med. 2022 Nov 10;193(Pt 2):595-609.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Anvari E, et al. The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. Free Radic Res. 2015;49(11):1308-18.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA